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Abstract
Background: Methods for describing one's confidence in the available evidence are useful for end-
users of evidence reviews. Analysts inevitably make judgments about the quality, quantity
consistency, robustness, and magnitude of effects observed in the studies identified. The
subjectivity of these judgments in several areas underscores the need for transparency in
judgments.
Discussion: This paper introduces a new system for rating medical evidence. The system requires
explicit judgments and provides explicit rules for balancing these judgments. Unlike other systems
for rating the strength of evidence, our system draws a distinction between two types of
conclusions: quantitative and qualitative. A quantitative conclusion addresses the question, "How
well does it work?", whereas a qualitative conclusion addresses the question, "Does it work?" In
our system, quantitative conclusions are tied to stability ratings, and qualitative conclusions are tied
to strength ratings. Our system emphasizes extensive a priori criteria for judgments to reduce the
potential for bias. Further, the system makes explicit the impact of heterogeneity testing, meta-
analysis, and sensitivity analyses on evidence ratings. This article provides details of our system,
including graphical depictions of how the numerous judgments that an analyst makes can be
combined. We also describe two worked examples of how the system can be applied to both
interventional and diagnostic technologies.
Summary: Although explicit judgments and formal combination rules are two important steps on
the path to a comprehensive system for rating medical evidence, many additional steps must also
be taken. Foremost among these are the distinction between quantitative and qualitative
conclusions, an extensive set of a priori criteria for making judgments, and the direct impact of
analytic results on evidence ratings. These attributes form the basis for a logically consistent system
that can improve the usefulness of evidence reviews.
Background
Systematic reviews, technology assessments, and clinical
practice guidelines all incorporate evidence-based conclu-
sions. The multifaceted nature of evidence, however, leads
to varying degrees of confidence in how well the evidence
supports conclusions drawn from it. For example, one is
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more confident in conclusions drawn from several well-
designed randomized controlled trials that find similar
effects than in conclusions drawn from a few poorly
designed trials with disparate results. Consequently,
methods for describing one's confidence in the available
evidence are useful for end-users of evidence-based docu-
ments. This confidence is embodied in strength-of-evi-
dence ratings.
In this article, we introduce a structured and transparent
system for rating the strength of a body of evidence per-
taining to a medical technology (see Note 1). We also
define the concept of the stability of evidence as distinct
from the strength of evidence. We identify the many judg-
ments inherent in the process of performing evidence
reviews, and then note how such judgments are incorpo-
rated within two prominent rating systems: the U.S. Pre-
ventive Services Task Force (USPSTF) system and the
Grades of Recommendation Assessment, Development
and Evaluation (GRADE) system [1-5]. Next, we describe
our system, and detail several of its unique attributes. We
present graphical illustrations of how our system provides
a logical framework to combine the judgments inherent
in evidence reviews. We then provide two complete exam-
ples to illustrate the system (one example for an interven-
tion and one for a diagnostic test).
Necessary Judgments
In performing an evidence review, an analyst must make
numerous judgments about the available evidence. For
many of these judgments, analysts at different centers
could reasonably disagree about the status of the evi-
dence. For example, one analyst may view a certain meth-
odological flaw as fatal, whereas another analyst may view
that same flaw as minor. This problem may be partially
addressed through the use of standardized quality instru-
ments. However, different centers tend to use different
instruments, which can lead to different assessments of
the quality of trials [6]. In the absence of empirical evi-
dence on the extent to which a particular methodological
flaw influences the results, the assessment of study quality
necessarily entails judgment.
The challenge of conflicting judgment is magnified when
several studies are available for review. With multiple
studies, the analyst must also consider the degree of con-
sistency among studies' results. Again, judgments must be
made and different analysts may reasonably disagree. For
example, different analysts may define "inconsistency"
using different threshold values for I2 (which is a statistical
measure of the consistency of study results). Other com-
ponents of the evidence analysis also require judgments,
including quantity, robustness, and magnitude of effect.
Definitions of these terms appear in Table 1, and addi-
tional judgments that are made during systematic reviews
are listed in Table 2.
In addition to these individual components (i.e., overall
quality, quantity, consistency, robustness, and magnitude
of effect of all evidence being considered), still another
layer of judgment is required: how to combine each of
these five components to produce a rating of the overall
"strength" of the evidence. Different analysts may disagree
about the relative importance of each component and
their interplay. For example, if there is one small but well-
conducted randomized controlled trial, how should one
reconcile the high quality but low quantity of this evi-
dence base to produce an overall strength rating? Or, how
should one interpret very large effects observed in subop-
timal study designs?
Table 1: A Guide to Terminology
Major components of evidence
Term Definition
Quality The extent to which studies are protected from bias
Quantity The number of studies and the number of patients
Consistency The extent to which different studies found similar results
Robustness The extent to which minor alterations in the data do not change conclusions drawn from that data
Magnitude of effect The effect size
Quantitative and qualitative conclusions
Type of conclusion: Quantitative Qualitative
Clinical interpretation: How well does it work? Does it work?
Type of rating: Stability Strength
Interpretation of rating: Confidence that future evidence will not indicate a 
different effect size
Confidence that future evidence will not indicate a different 
direction of effect
Possible ratings: High, Moderate, Low, or Unstable Strong, Moderate, Weak, or InconclusiveBMC Medical Research Methodology 2006, 6:52 http://www.biomedcentral.com/1471-2288/6/52
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With all the judgments necessary, two different analysts,
when faced with exactly the same clinical question and
exactly the same evidence base, may have different degrees
of confidence in their conclusions. In some instances, this
Table 2: Judgments Involved in Systematic Reviews
Judgments pertaining to study quality assessment
• What method will be used to assess study quality?
• If a quality scale is to be used, what scoring method will apply?
• What is the threshold for excluding a study from analysis due to poor quality?
• How will the individual study quality ratings be summarized to yield a single overall rating of quality to the evidence base (High, Moderate, or 
Low)?
Judgment pertaining to sufficient evidence for quantitative estimate
• What is the minimum number of studies required to permit a quantitative estimate?
• What is the minimum percentage of studies reporting accurate information (i.e., calculable effect sizes) required to permit a quantitative estimate?
• What imputation methods will be used for studies that did not report sufficient information for a calculable effect size?
Judgments pertaining to initial meta-analysis
• What effect size measure will be used?
• How will heterogeneity be measured (Q or I2)?
• What is the threshold for considering an evidence base heterogeneous?
• Will the summary effect size estimate be derived from a fixed-effects or random-effects meta-analysis?
Judgments pertaining to quantitative robustness testing
• What robustness tests will be used?
• If a cumulative meta-analysis is one of the robustness tests, will it be a fixed-effects or random-effects model?
• If a cumulative meta-analysis is one of the robustness tests, in what order will studies be entered into the cumulation?
• If a cumulative meta-analysis is one of the robustness tests, how many steps (i.e., study removals) will be examined to determine robustness?
• If a cumulative meta-analysis is one of the robustness tests, what threshold for a change in the summary effect size will be used to determine 
robustness?
• If publication bias testing is one of the robustness tests, which method of testing for publication bias will be used?
• If confidence interval width is one of the robustness tests, how narrow must the interval be for the summary estimate to be considered robust?
• Will overall robustness be judged based on passing all of the robustness tests, or simply a majority, or what percentage?
Judgments pertaining to meta-regression
• What is the minimum number of studies required to perform meta-regression?
• Which covariates will be included in multiple regression models?
• How many covariates are permitted in any given regression model?
• Does "explaining heterogeneity" require a statistically significant covariate, or the lack of resultant heterogeneity, or both of these?
• What robustness tests will be performed for the meta-regression?
Judgments pertaining to qualitative robustness testing
• What robustness tests will be performed?
• If a cumulative meta-analysis is one of the robustness tests, in what order will studies be entered into the cumulation?
• If a cumulative meta-analysis is one of the robustness tests, how many steps (i.e., study removals) will be examined to determine robustness?
Other judgments
• What is the size of a lowest possible effect that is still clinically important?
• What is the p value for statistical significance?
• What is the definition of a large magnitude of effect?
• How will qualitative consistency be defined (based on point estimates, confidence intervals, some percentage of studies, etc)?BMC Medical Research Methodology 2006, 6:52 http://www.biomedcentral.com/1471-2288/6/52
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discrepancy could be so large that the two analysts reach
different overall conclusions. In a pilot study of inter-
reviewer agreement, the GRADE group asked 17 experi-
enced reviewers to rate the strength of the evidence for
each of 46 outcomes within 12 systematic reviews [4].
Complete agreement occurred for only three outcomes
(6%). The median kappa statistic of agreement was only
0.09, suggesting substantial inter-reviewer differences in
evidence ratings. Although this study was conducted
when the GRADE system was relatively new (and, there-
fore, these results may underestimate the true amount of
agreement), the results do illustrate that even experienced
reviewers can disagree about the strength of the evidence.
The subjectivity of judgments at several points in the sys-
tematic review process underscores the need for transpar-
ency. With transparent judgments, the end users of the
review (including other analysts) can decide for them-
selves whether the judgments are reasonable.
Currently Available Rating Systems
Numerous rating systems designed to assess the strength
of a body of evidence have been proposed. Several of
these were reviewed in a 2002 report from the Research
Triangle Institute-University of North Carolina Evidence-
based Practice Center (RTI-UNC EPC) [7]. This report
focused on three components of a rating system: quality,
quantity, and consistency. The report incorporated mag-
nitude of effect within the quantity category, and did not
mention robustness explicitly. Below, we highlight two
major rating systems.
One prominent system is the Third U.S. Preventive Serv-
ices Task Force (USPSTF) system [1]. This system, which is
outlined in Table 3, employs ratings of the evidence at
each of three strata: the individual study, the group of
studies providing evidence on a single outcome, and the
full body of evidence on all outcomes. If the overall rating
at the third stratum is Good or Fair (i.e., at least some net
benefit), the USPSTF system then incorporates magnitude
of effect, separately for benefits and harms. Here, the goal
is to weigh the relative benefits and harms in order to esti-
mate the overall net benefit of the technology. Such
weighting requires yet another layer of judgment: the rel-
ative importance of several different outcomes. One criti-
cism of the USPSTF system, and several similar systems, is
the lack of transparency in judgments [2]. Although the
USPSTF system lists numerous factors one should con-
sider when making judgments, and narrative text is used
to explain these judgments, there is no formal mechanism
(e.g., a point system) that would allow end users to repro-
duce these judgments. Furthermore, the manner in which
judgments are combined in the USPSTF system is not
specified.
One major effort to create a formal point system is the
GRADE system [2-5] The GRADE approach (Table 4)
emphasizes the primacy of study design, which is used to
Table 3: USPSTF System for Evaluating the Quality of Evidence (Harris et al. 2002)[1]
Level of evidence: Individual study
Criteria for judging quality:
• Internal validity – based on a series of separate, specific criteria for systematic reviews, RCTs, cohort studies, case-control studies, and 
diagnostic accuracy studies
• External validity – degree to which the study is generalizable to the population of interest and conditions of typical clinical practice
Level of evidence: Linkage (key question) in the analytic framework
Criteria for judging quality:
• Aggregate internal validity of studies addressing the linkage
• Aggregate external validity of studies addressing the linkage
• Coherence/consistency of studies addressing the linkage
Level of evidence: Entire preventive service
Criteria for judging quality:
• Quality of the evidence for each linkage in the analytic framework
• Degree to which a complete chain of linkages supported by adequate evidence connects the preventive service to health outcomes
• Degree to which the complete chain of linkages "fit" together a
• Degree to which the evidence connecting the preventive service and health outcomes is "direct" b
a"Fit" refers to the degree to which the linkages refer to the same population and conditions. For example, if studies of a screening linkage identify 
people who are different from those involved in studies of the treatment linkage, the linkages are not supported by evidence that "fits" together.
b"Directness" of evidence is inversely proportional to the number of bodies of evidence required to make the connection between the preventive 
service and health outcomes. Evidence is direct when a single body of evidence makes the connection, and more indirect if two or more bodies of 
evidence are required.BMC Medical Research Methodology 2006, 6:52 http://www.biomedcentral.com/1471-2288/6/52
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set a starting quality grade. Then, other components are
considered which may increase or decrease the grade (see
Table 4 under quality of evidence for each outcome). The
GRADE approach results in one of four outcome-specific
grades: High, Moderate, Low, and Very Low. Definitions
of these terms are based on the likelihood that further evi-
dence will change one's confidence in the size of the
effect. The American College of Chest Physicians Task
Force recently described the use of a revised GRADE sys-
tem that combined Low and Very Low into one category
(Low) [5].
Within the various increments and decrements in GRADE,
several implicit judgments are necessary. For example,
what is a "serious" limitation in study quality or an
"important" inconsistency among effect sizes? Such judg-
ment is an inevitable part of performing systematic
reviews, as discussed earlier, and the GRADE group readily
acknowledges the need for judgment. Further, a key moti-
vation behind the GRADE effort was a need for "explicit
definitions" and "sequential, explicit judgments,"[2] and
the GRADE system represents an importance advance
towards transparency.
An explicit system for combining these judgments (i.e., a
point system) is a particular strength of the GRADE
approach. This system defines precisely how the various
aspects of the evidence are combined to arrive at an over-
all grade of the evidence for each outcome. Thus, if a user
made different judgments than the analyst, then the user
could apply the GRADE point system accordingly, and
possibly arrive at a different rating of the evidence. For
example, suppose an analyst judged that there were
important inconsistencies in the data for a certain out-
come, but a user examined the same data and believed
that the inconsistency was unimportant. Using the
GRADE system, the user could then increase the final
grade by one level.
In addition to USPSTF and GRADE, several other promi-
nent systems for rating the strength of evidence have been
proposed by the American College of Chest Physicians
(ACCP) [8], the Australian National Health and Medical
Research Council (ANHMRC) [9], the Oxford Centre for
Evidence-Based Medicine (OCEBM) [10], the Scottish
Intercollegiate Guidelines Network (SIGN) [11], and the
U.S. Task Force on Community Preventive Services (UST-
FCPS) [12]. Each of these systems were reviewed by the
GRADE group, which concluded that these systems all
have important shortcomings [2].
A New System
We now describe a new system for rating the strength of
evidence. Like the GRADE system, our system emphasizes
the need for making judgments explicit, and uses the
equivalent of a formal point system for rating the strength
of a body of evidence. Our system, however, is unique in
several fundamental respects. Below, we describe the three
prominent areas of uniqueness: 1) the distinction
between quantitative and qualitative conclusions; 2)
extensive use of a priori criteria for judgments; and 3) the
direct impact of meta-analysis and sensitivity analysis on
evidence ratings. We then provide details on the system
itself, including graphical depictions of how judgments
Table 4: The GRADE System for Grading Quality of Evidence and Strength of Recommendations[2,5]
Quality of evidence for each outcome (high, moderate, or low) – based on the following criteria:
• Study design– grade of high or low assigned based on design (RCT = high, observational study = low)
• Study quality– Detailed study methods and execution.
1) Limitations in quality can decrease grade one or two levels.
2) Evidence of reporting bias can also decrease grade one level.
3) Grade can be increased one level if all plausible confounders would have reduced the treatment effect.
• Consistency of results– The level of similarity of estimates of effects across studies.
1) Important inconsistency can decrease grade one level.
• Directness of evidence– the extent to which the people, interventions, and outcome measures are similar to those of interest.
1) Some or major uncertainty about directness lowers the grade one or two levels.
• Other considerations
1) Magnitude of effect can increase the grade of evidence. Strong evidence of association (significant relative risk of >2 or <0.5 based on 
consistent evidence from 2 or more observational studies with no plausible confounders) increases the grade by one level. Very strong 
evidence of association (significant relative risk of >5 or <0.2 based on direct evidence with no major threats to validity) increases the grade 
by two levels.
2) Evidence of a dose-response gradient increases the grade by one level.
3) Imprecise or sparse data can lower the grade by one level.
Relative importance of outcomes – included outcomes should be critical or important (but not critical) to a decision
Overall quality of evidence – judged across outcomes based on the lowest quality of evidence for any of the critical outcomes
Balance of benefits and harms – classified as net benefits, trade-offs, uncertain trade-offs, or no net benefits based on the important health 
benefits and harms
Balance of net benefits and costs – are incremental health benefits worth the costs?
Strength of recommendation – the extent to which one can be confident that adherence to a recommendation will do more good than harmBMC Medical Research Methodology 2006, 6:52 http://www.biomedcentral.com/1471-2288/6/52
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can be combined (Figure 1, Figure 2, Figure 3, Figure 4,
and Figure 5).
Our system is designed to rate the stability and strength of
evidence for each outcome an analyst chooses to evaluate
(see Note 2), and is not intended to produce overall rec-
ommendations for (or against) a technology. By contrast,
both USPSTF and GRADE rate the strength of the overall
evidence for the technology (which is often based on sev-
eral outcomes), and the strength of a recommendation
about the technology. The first involves assessing the
overall net benefit by balancing the benefits and harms.
The second entails more judgments (listed in the USPSTF
methods article) about the importance and impact of cost,
ethics, law, patient expectations, and societal expectations
[1]. Also, unlike GRADE and USPSTF, our evidence rating
system focuses on only the internal validity of the evi-
dence. Questions about generalizability can be addressed
outside the scope of the rating system. We are currently
examining how well our evidence rating system can be
applied within the overall GRADE framework.
Quantitative and Qualitative Conclusions
Our system draws a distinction between two types of con-
clusions: quantitative and qualitative (see the bottom half
of Table 1). The quantitative conclusion addresses the
question, "How well does it work?", and we refer to the
corresponding rating as a "stability" rating. By contrast,
the qualitative conclusion addresses the more general
question, "Does it work?", and we refer to the rating of the
evidence pertaining to this conclusion as a "strength" rat-
ing. Thus, a quantitative conclusion characterizes the size
of the effect, whereas a qualitative conclusion character-
izes the direction of the effect.
This key distinction allows one to draw a strong qualita-
tive conclusion in the face of quantitatively heterogeneous
data. Such a situation arises when the results of all studies
included in an evidence base demonstrate efficacy, but the
magnitude of measured treatment effect differs considera-
bly across studies.
This situation is illustrated in a recent systematic review
on drug-eluting stents for coronary artery disease [13].
Entry Into System Figure 1
Entry Into System.BMC Medical Research Methodology 2006, 6:52 http://www.biomedcentral.com/1471-2288/6/52
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This review included 14 randomized trials that compared
drug-eluting stents to bare metal stents. Each trial reported
the percentage of patients in each arm who underwent tar-
get lesion revascularization (TLR) after stent implantation
(Figure 6). A homogeneity test of these data identified
substantial heterogeneity among trial results (Q = 59, p <
0.0001, I2 = 78%), and subsequent meta-regression anal-
yses did not explain this heterogeneity. Consequently, we
refrained from presenting an estimate of the size of treat-
ment effect. However, all trials found that TLR rates were
lower after implantation of a drug-eluting stent than after
a bare metal stent, and the random-effects meta-analytic
confidence interval demonstrated this clear direction of
effect (see the bottom of Figure 6). Thus, although one can
have little confidence in the accuracy of a single quantita-
tive estimate of the effect size, one can have high confi-
dence that drug-eluting stents are effective in reducing TLR
rates. Thus, the quantitative/qualitative distinction also
underpins two notions of consistency. The first is quantita-
tive consistency: do the studies report similar effect sizes?
The second is qualitative consistency: do the studies
report the same direction of effect?
Another important purpose of differentiating quantitative
from qualitative conclusions is to acknowledge the differ-
ent needs of those who utilize systematic reviews. Some
users are primarily interested in obtaining an estimate of
the amount of benefit (or harm) associated with a tech-
nology. Other users are simply interested in whether the
technology provides any benefit at all. If a systematic
review provides both kinds of conclusions, then both
needs are met.
No other system for rating medical evidence distinguishes
explicitly between quantitative and qualitative conclu-
sions. We believe the distinction is critical to ensure that
systematic reviews provide a full picture of the evidence.
The GRADE group defines their ratings as the likelihood
that further evidence will change one's confidence in the
size of the effect, which appears to be a purely quantitative
definition. The USPSTF system does not state whether its
ratings refer to quantitative conclusions, qualitative con-
clusions, or both.
In our system, stability and strength ratings are not inde-
pendent. Logically, evidence that permits a "highly stable"
estimate of treatment effect (e.g., an odds ratio of 3.25 in
favor of treatment) must also permit a "strong" conclu-
sion about the direction of effect (e.g., that the odds ratio
favors treatment). Thus, one built-in feature of our system
is that the stability rating sets a lower bound on the
strength rating. This means that "moderate" stability can
be accompanied by a strength rating no lower than "mod-
Overview of the High Quality Arm Figure 2
Overview of the High Quality Arm.BMC Medical Research Methodology 2006, 6:52 http://www.biomedcentral.com/1471-2288/6/52
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erate", and "low" stability can be accompanied by a
strength rating no lower than "weak."
Crucial to understanding the results of a systematic review
is understanding whether the results are clinically impor-
tant; statistically significant results do not necessarily rep-
resent a clinically important effect. This has been
mentioned in many systematic reviews [14-18], and our
quantitative/qualitative distinction provides an analytic
approach. To address clinical importance in our system,
one first defines precisely the magnitude of effect that is
considered clinically important (e.g., a difference of 0.5%
in HbA1c in treatments for diabetes). Then, clinical impor-
tance can be addressed as a qualitative question: "Is the
difference clinically important?" This question is
addressed analytically via a comparison of effect sizes to
an effect size predefined as clinically important.
Extensive A Priori Criteria for Judgments
Most systematic reviews use a priori inclusion criteria to
reduce the potential for bias in judgments about which
studies to include. Some also make an a priori judgment
about which instrument will be used to assess study qual-
ity. However, many other judgments are still susceptible
to bias. To reduce this potential, our system specifies the
use of a priori judgments wherever possible. For example,
the system requires that one specify a priori quantitative
definitions of "consistent" and "robust" effects. Also, the
analyst must pre-specify the minimum percentage of
included studies that reported the outcome of interest in
order to permit a meta-analytic estimate of effect size. If
only a small percentage of included studies reported the
outcome, selective outcome reporting may have occurred,
thereby biasing the meta-analytic summary statistic. For
study quality, the analyst must identify not only the
instrument to be used, but also the scoring system (if
High Quality Arm: Homogeneous Data Figure 3
High Quality Arm: Homogeneous Data.BMC Medical Research Methodology 2006, 6:52 http://www.biomedcentral.com/1471-2288/6/52
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used) and the thresholds that define study quality catego-
ries (high, moderate, or low quality). Even the threshold
for statistical significance (which does not have to be the
conventional 0.05 in all contexts because some clinical
contexts may warrant greater or lesser concern about Type
1 errors) must be specified beforehand. To address the
question of clinical importance, the minimum level con-
sidered to be clinically important must also be deter-
mined a priori. These definitions, and others, are discussed
further in the section entitled "How the System Works".
Consequences of Meta-Analysis and Sensitivity Analysis
Many systematic reviews report the results of meta-analy-
ses, and some also describe sensitivity analyses. Often,
however, the results of these statistical analyses are not
explicitly tied to ratings of the evidence. In this section, we
describe how our system links analytic results to both sta-
bility and strength ratings.
The purpose of meta-analysis is not just to obtain a sum-
mary estimate of treatment effect, but also to test the data
for consistency (heterogeneity testing). This latter purpose
is typically accomplished using the Q-statistic, and more
recently, I2 [19,20] If important heterogeneity is detected,
our system requires that, whenever appropriate (e.g.,
when the evidence base is large enough), the analyst
explore potential sources of this heterogeneity using meta-
regression. If heterogeneity cannot be explained by meta-
regression, then our system precludes one from present-
ing a single summary estimate of treatment effect (i.e., a
stability rating of "Unstable") (see Note 3). Some investi-
gators advocate the use of a random effects summary sta-
High Quality Arm: Heterogeneous Data Figure 4
High Quality Arm: Heterogeneous Data.BMC Medical Research Methodology 2006, 6:52 http://www.biomedcentral.com/1471-2288/6/52
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tistic in this situation. However, unexplained
heterogeneity could be due to differences in patient pop-
ulations, and/or the way a treatment is administered. Our
view is that computing a single summary estimate is not
warranted when the evidence demonstrates the existence
of multiple estimates.
Although our system precludes the use of random-effects
models in determining a single summary estimate of treat-
ment effect, the use of these models does have an impor-
tant role. This role involves a summary of the evidence to
support a qualitative conclusion. Even if there is substan-
tial unexplained heterogeneity, the evidence may still
indicate a consistent direction  of effect. The confidence
interval (CI) around the random effects summary statistic,
which incorporates both within-study and between-study
variance, may lie fully above 0 or below 0 (see Note 4).
This CI, therefore, is suitable for determining whether the
data suggest a clear direction of effect.
Other systems, such as GRADE and USPSTF, are largely
silent on the role of meta-analysis in systematic reviews.
Our system uses meta-analysis and meta-regression
(when clinically appropriate) to increase statistical power
and employ precise study weights; furthermore, the sys-
tem is unique in incorporating the results of these analy-
ses into evidence ratings.
We now turn to the role of sensitivity analysis in our sys-
tem. In this context, consider that the goal of rating evi-
dence is to assess the likelihood that future evidence will
indicate something different than what current evidence
High Quality Arm: Small Evidence Base Figure 5
High Quality Arm: Small Evidence Base.BMC Medical Research Methodology 2006, 6:52 http://www.biomedcentral.com/1471-2288/6/52
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indicates. If a large amount of consistent evidence has
already accumulated, then future evidence is unlikely to
alter the overall strength or stability. Conversely, conclu-
sions based on only a small amount of accumulated evi-
dence may easily change when a single new study is
published.
Considered from this perspective, we argue that sensitivity
analysis (see Note 5) can substitute for certain judgments
about quantity. The idea is that if the conclusion from a
meta-analysis depends critically on only one or a few stud-
ies in that analysis (or if there is reason to suspect that not
all relevant studies are available), then the conclusion
may not be robust. Such dependence suggests that a future
study may alter conclusions based on currently available
studies. Consequently, our system downgrades the stabil-
ity or strength ratings accordingly. Although there is a
widespread sense that sensitivity analysis should be incor-
porated into an analysis, the system is unique in offering
explicit rules for how to gauge the impact of the results of
sensitivity analyses on one's confidence in the available
evidence.
Sensitivity analysis can obviate the need for certain subjec-
tive judgments about the magnitude of effect. Some rating
systems (e.g., GRADE) employ such judgments, and if the
observed effect is very large, the evidence receives a higher
strength rating. Presumably, this is because a very large
effect is less likely to be overturned by future evidence and
is therefore more robust. However, if there are sufficient
Forest Plot Demonstrating the Quantitative/Qualitative Distinction Figure 6
Forest Plot Demonstrating the Quantitative/Qualitative Distinction. Plot showing the results of 14 randomized trials 
that compared drug-eluting stents (DES) to bare metal stents (BMS) and reported the percentages of patients who underwent 
target lesion revascularization after stent implantation. Sizes of the squares are proportional to study size, and 95% confidence 
intervals are shown as horizontal lines. There was unexplained heterogeneity among the trial results, so we did not estimate 
the size of the difference between groups. However, the random-effects meta-analytic confidence interval at the bottom of the 
plot showed the summary statistic was statistically significant.BMC Medical Research Methodology 2006, 6:52 http://www.biomedcentral.com/1471-2288/6/52
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studies to perform direct robustness tests via sensitivity
analyses, then we advocate doing so, in lieu of making
judgments about effect sizes. A meta-analytic sensitivity
analysis incorporates effect sizes and confidence intervals
from all studies, so that the test is empirically-based.
As with consistency, the quantitative/qualitative distinc-
tion helps clarify two notions of robustness. Quantitative
robustness concerns the degree to which the summary
effect size from meta-analysis tends to change based on
relatively small alterations in the data. To assess quantita-
tive robustness, one can perform successive meta-analyses
and observe the relative changes in the summary estimate.
If the changes in the estimate exceed a predetermined tol-
erance level, then the original summary estimate is not
quantitatively robust. Qualitative robustness refers to
whether the evidence base yields the same qualitative gen-
eral conclusion upon alterations of the data. To assess it,
one can again perform successive meta-analysis, but in
this case the issue is whether the confidence intervals
around summary statistics consistently indicate the same
direction of effect.
For example, one qualitative robustness test we have
employed utilized cumulative meta-analysis [21]. In a
report on treatments for bulimia [22], we included seven
Example of a Qualitative Robustness Test Figure 7
Example of a Qualitative Robustness Test. Cumulative meta-analytic-test of the qualitative of seven randomized trials 
that compared pharmacotherapeutic treatment for bulimia to placebo and reported mean purging frequency. We performed a 
cumulative meta-analysis in which the study with the largest weight was entered first (the topmost horizontal segment in the 
plot), and then the study with the next largest weight was entered (the second one from the top), etc. Each horizontal segment 
in the plot is a 95% confidence interval around a random-effects summary Hedges' d, a standardized mean difference. (The 
point estimates are not shown to clarify that the analysis focuses only on confidence intervals, not point estimates). In each of 
the last five analyses, the effect was statistically significant in the same direction. This met our a priori definition of qualitative 
robustness, which was that the qualitative conclusion must have remained the same after each of the last three or more studies 
were added.BMC Medical Research Methodology 2006, 6:52 http://www.biomedcentral.com/1471-2288/6/52
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randomized trials that compared the efficacy of pharma-
cotherapy to placebo and reported mean purging fre-
quency. A random-effects meta-analysis found that
medication yielded significantly greater effects than pla-
cebo (i.e., lower purging frequency). We tested the quali-
tative robustness of this finding in the following manner
(see Figure 7). The 95% confidence interval of the study
with the largest weight (as determined by the inverse of
the variance) in the meta-analysis was plotted first (the
topmost horizontal segment in the figure). Then we
added the study with the next largest weight, and plotted
the corresponding random-effects 95% confidence inter-
val for the two-study meta-analysis (the second segment
from the top in the figure). Then we continued adding
studies, one at a time, until all meta-analytic confidence
intervals were plotted. A priori, we had defined a qualita-
tive robust evidence base as one where each of the last
three cumulative meta-analyses yielded the same qualita-
tive conclusion. Therefore, we deemed this evidence base
to be qualitatively robust.
How the System Works
The system is shown graphically in five figures:
• Entry into system (Figure 1)
￿ Overview of the high quality arm (Figure 2)
￿ Homogeneous data (Figure 3)
￿ Heterogeneous data (Figure 4)
￿ Small evidence base (Figure 5)
An important feature of this system is that every question
illustrated in the figures requires a set of a priori criteria.
Nearly all of these a priori criteria are operational defini-
tions that are quantitative. The use of a priori criteria helps
to reduce bias and subjectivity, as discussed above, and
the use of quantitative definitions increases transparency.
This system assumes that the assessor has already applied
appropriate inclusion/exclusion criteria and has excluded
from the analysis any study with fatal flaws.
The initial entry into the system occurs with an assessment
of the quality of the evidence for a specific outcome (Fig-
ure 1), which we consider to be the most important aspect
of the evidence. Quality sets an upper bound on the sta-
bility and strength ratings (e.g., moderate strength is only
possible for data that is, at minimum, moderate quality).
Although quality evaluation can be performed with a
checklist or scale, any reasonable method for separating
the evidence base into different categories of quality will
suffice. After an evaluation of individual study quality,
studies are judged to be high, moderate, low, or very low
quality. Studies of very low quality are always excluded
from the evidence base, and the analyst may also choose
to exclude low or even moderate quality studies as well.
The analyst must choose a method for aggregating the
quality of the individual studies to obtain an overall qual-
ity rating for the evidence base and then enter the high,
moderate, or low quality arm of the system. Within these
arms, the system further assesses the quantity, consist-
ency, robustness, and (in some instances) magnitude of
effect to determine the stability and strength of the evi-
dence.
Figure 2 through Figure 5 detail the high quality arm of
the system. The top half of each figure includes all of the
questions and decisions that impact stability ratings (and
quantitative conclusions), while the bottom half includes
all of the questions and decisions that impact strength rat-
ings (and qualitative conclusions). The moderate and low
quality arms of the system are not shown because all
aspects of this system are already displayed in the high
quality arm.
At the top of these pathways, one first considers whether
the evidence base is sufficient to provide a single quanti-
tative estimate of the effect size. We generally require at
least three studies, but other investigators may wish to set
this criterion higher (e.g., five studies). Additionally, the
system requires that a certain percentage of the studies
(e.g., 80% or more) must have calculable effect sizes (that
can be determined without imputation). If these criteria
are not met, then one proceeds to Figure 5 (small evidence
base). If these criteria are met, then one tests the quantita-
tive consistency of the data using a heterogeneity measure
such as Q or I2. Under homogeneity, one proceeds to Fig-
ure 3, whereas under heterogeneity, one proceeds to Fig-
ure 4.
Before detailing the steps in Figures 3 and 4, we must first
define the concept of "informativeness", a concept crucial
to interpreting the results of individual studies and meta-
analyses. Figure 8 illustrates four different effect sizes (A
through D) that are considered informative based on cri-
teria discussed in Armitage and Berry [23]. These effects
are informative because the confidence intervals around
the summary effect estimates support one of four qualita-
tive conclusions: A) the treatment is beneficial and the
effect is clinically important (i.e., the lower 95% confi-
dence interval around the meta-analytic summary statistic
is greater than the effect size deemed clinically impor-
tant); B) the treatment is beneficial but the effect may or
may not be clinically important (i.e., the lower 95% con-
fidence interval around the meta-analytic summary statis-
tic is greater than zero but less than a clinically important
effect); C) the treatment is beneficial but the effect is not
clinically important (the 95% confidence interval isBMC Medical Research Methodology 2006, 6:52 http://www.biomedcentral.com/1471-2288/6/52
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between zero and the effect deemed clinically important);
or D) the treatment is not beneficial (the 95% confidence
interval overlaps zero and does not overlap the line of
clinical importance) (see Note 6). By contrast, example E
in Figure 8 would be considered inconclusive (non-
informative) because the 95% confidence interval over-
laps both zero and the line of clinical importance. Note
that this use of "informativeness" accounts for the statisti-
cal power of the evidence base, another unique feature of
our system (for a related discussion see Armitage and
Berry) [23]. Moreover, by incorporating clinical impor-
tance into the system, we provide clinical meaning for the
end-users of systematic reviews and other evidence-based
documents.
In the homogeneous pathway (Figure 3), one performs a
meta-analysis to combine the study results. If the meta-
analytic summary statistic is not informative, then no con-
clusions are reached. If the summary statistic is informa-
tive, one tests the robustness of the findings through
sensitivity analysis (e.g., removal of one study at a time).
If the meta-analytic summary statistic passes the robust-
ness tests, the estimate is quantitatively robust. This pro-
duces a high stability rating for the quantitative estimate,
which leads directly to a strong qualitative conclusion.
The logic behind this implication is that if one is confi-
dent in the specific estimate of the effect, one is automat-
ically confident in the general direction of that effect.
Continuing within Figure 3, if the findings are not quan-
titatively robust, one re-examines the sensitivity analyses
Informative and Non-Informative Effect Sizes Figure 8
Informative and Non-Informative Effect Sizes. This figure is adapted from Armitage and Berry.[23] Each open diamond 
denotes a hypothetical meta-analytic summary statistic, and the horizontal segments denote 95% confidence intervals. The 
dashed vertical line indicates the effect size that was determined a priori to represent the minimum effect size that is consid-
ered clinically important. A meta-analytic summary statistic is considered informative if its confidence interval either excludes 0 
or excludes a clinically important effect (or both). Thus, meta-analyses A through D each show informative results, whereas 
meta-analysis E shows a non-informative result.BMC Medical Research Methodology 2006, 6:52 http://www.biomedcentral.com/1471-2288/6/52
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to determine qualitative robustness (e.g., do any of the
last three analyses in a cumulative meta-analysis of a given
data set lead to a different qualitative conclusions?). Addi-
tional sensitivity analyses that can be used include remov-
ing each study separately or changing the effect size
statistic (e.g., using Cohen's h instead of an odds ratio).
We also consider tests for publication bias to be a form of
sensitivity analysis, although publication bias testing
requires a minimum number of available studies.
Whether the findings are qualitatively robust determines
whether one reaches a strong or moderate qualitative con-
clusion. Also, one can only reach a strong conclusion from
a high quality evidence base. In the moderate and low
quality arms, the qualitative conclusion can never be
stronger than moderate or weak, respectively.
Figure 4 illustrates the branch followed when an evidence
base has enough studies with calculable effect sizes to
potentially reach a quantitative effect estimate, but the
heterogeneity test indicates significant differences among
the studies. If this heterogeneity can be explained using
meta-regression, one can still reach a quantitative conclu-
sion. The quantitative conclusion is the conclusion
reached about the regression coefficients, including the
intercept. For example, if gender is the variable that
explains heterogeneity, one might have a conclusion such
as "treatment X improved symptoms twice as effectively in
women as in men". If meta-regression is not possible or
does not explain heterogeneity, no quantitative conclu-
sion is possible. However, one can still perform a random-
effects meta-analysis which, if informative, may allow a
qualitative conclusion.
Figure 5 illustrates what occurs when the evidence base is
too small or otherwise insufficient to allow a quantitative
conclusion. Some studies may not report effects sizes and
standard errors (nor sufficient information for the analyst
to calculate both measures). The analyst must acknowl-
edge and adjust for the existence of such studies. This
adjustment may require the estimation or imputation of
effect sizes in certain studies [24]. The full evidence base is
then assessed in a random-effects meta-analysis to deter-
mine if a qualitative conclusion can be reached.
If there are only two studies and both have calculable
effect sizes, one performs a random-effects meta-analysis
which, if informative, allows a qualitative conclusion. Of
note, meta-analysis of a two-study evidence base is not
required in the moderate quality arm, where a conclusion
would require both studies to have a statistically signifi-
cant effect. In the low quality arm, a minimum of three
studies is required to reach any conclusion. A qualitative
conclusion is also possible for two studies with imprecise
effect sizes (that cannot be combined) if both studies are
informative and show qualitatively consistent results. If
two studies are qualitatively inconsistent or not informa-
tive when combined, the findings are inconclusive. If
there is only one study, a large effect size is required to
allow a weak qualitative conclusion (note that one cannot
reach a conclusion if the single study is of moderate or low
quality).
Examples
In this section, we provide two example applications of
our evidence rating system. In addition to illustrating var-
ious aspects of the system, we show how the system can
be used in conjunction with simple declarative conclu-
sions that are tied to the stability and strength ratings. The
first example involves drug-eluting stents (DESs) for the
treatment of coronary artery disease, and the second
example involves positron emission tomography (PET) in
the staging of lymphoma.
Example #1: Comparison between Drug-Eluting Stents and Bare-
Metal Stents for the Treatment of Coronary Artery Disease
In a 2006 report, we examined the evidence comparing
the safety and efficacy of drug-eluting stents (DESs) and
bare-metal stents for the treatment of angina [13].
Evidence base
We included 14 randomized trials that compared drug-
eluting stents to bare metal stents and reported the per-
centage of patients in each group who underwent target
lesion revascularization (TLR) after stent implantation.
The trials enrolled a total of 7,006 patients. We addressed
the quantitative issue of the size of the difference in over-
all TLR rates and also the qualitative issue of whether there
was any difference in overall TLR rates between the two
types of stents.
Study quality assessment
To assess the quality of the studies, we applied a quality
rating scale, and determined (using a priori definitions of
high, medium, and low quality) that the evidence base
was of high quality.
Sufficient data for quantitative estimate
In order to attempt a quantitative estimate of the effect, we
required a priori that there must be at least three studies,
and at least half of the included studies reported sufficient
information for us to calculate effect sizes and confidence
intervals. All 14 studies reported such information, so we
attempted to make a quantitative estimate.
Heterogeneity testing
A priori, we defined quantitative consistency based on
thresholds for Q and I2. These thresholds were a p value
for the Q statistic less than 0.10 (which would mean
quantitative inconsistency) and I2 < 50% (which would
also mean quantitative inconsistency). We used a p valueBMC Medical Research Methodology 2006, 6:52 http://www.biomedcentral.com/1471-2288/6/52
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of 0.10 because of the known low power of Q. We used a
threshold of 50% for I2 because this value represents mod-
erate heterogeneity [19,20] For this evidence base, we per-
formed a meta-analysis using Cohen's h and found
substantial heterogeneity (I2 = 78%, Q = 59, p value for Q
was less than 0.000001).
Meta-regressions to explain heterogeneity
Given the heterogeneity of effect sizes, we performed
meta-regressions in an attempt to explain why study
results differed. Not all potential covariates could be
examined because not all studies reported some covari-
ates. The three covariates we could examine were drug
type (paclitaxel or sirolimus), mean target vessel diameter,
and mean target lesion length. None of these three factors
were sufficient to explain the observed heterogeneity.
Therefore, we did not draw a quantitative conclusion for
the outcome of TLR rates. However, we proceeded to a
qualitative analysis using a random-effects model to
determine whether the evidence permitted a qualitative
conclusion.
Stability rating
We rated the stability of the evidence as Unstable, due to
the unexplained heterogeneity among effect sizes.
Informativeness
We performed a random-effects meta-analysis using
Cohen's h. The summary statistic was statistically signifi-
cant (lower TLR rates among patients who received DESs)
and clinically important (because TLR is an important
patient-oriented outcome, we defined clinical importance
a priori as any statistically significant effect). This meant
that the evidence was informative.
Qualitative robustness testing
A priori, we defined a quantitatively robust evidence base
as one in which the confidence intervals of the last three
cumulative, random-effects meta-analyses remained fully
on the same side of zero after; 1) removal of the study
with the smallest weight (i.e., the lowest precision), and,
2) after the additional removal of the study with the sec-
ond smallest weight in the meta-analysis. Because the evi-
dence base met both of these criteria, we deemed the
evidence base to be qualitatively robust.
Strength rating
The strength rating of the evidence for a qualitative differ-
ence in TLR rates was Strong, because the meta-analysis
was of high quality studies, and was informative and qual-
itatively robust.
Wording of conclusions
The conclusions for this outcome were phrased in the fol-
lowing manner:
The use of DESs (Cypher and TAXUS stents) leads to lower
overall TLR rates than use of bare-metal stents in patients
with angina at 6 to 12 months following stent implanta-
tion. (Strength of evidence: Strong)
￿ Due to unexplainable differences among the findings of
different trials, one cannot accurately determine how
much lower these rates are at 6 to 12 months following
implantation of a DES.
Example #2: Positron Emission Tomography for the Staging of 
Lymphoma
In a 2006 report prepared by ECRI's Health Technology
Assessment Information (HTAIS) under contract to TRI-
CARE Management Activity (see Note 7), we assessed the
use of positron emission tomography (PET) in the staging
of lymphoma. The reference standard for determining
whether lymphoma has reached Stage IV is a bone mar-
row biopsy typically taken from the iliac crest. PET may
potentially help patients avoid the invasiveness of bone
marrow biopsy, depending on how accurately it detects
bone marrow infiltration.
Evidence base
We included five diagnostic cohort studies that performed
PET as well as bone marrow biopsy and also reported suf-
ficient information for the calculation of sensitivity and
specificity. The studies reported data on a total of 243
patients. Because our research question was to determine
a quantitative estimate of diagnostic accuracy, we did not
attempt to draw a qualitative conclusion. Therefore, the
text below refers only to the stability rating, not to a
strength rating.
Study quality assessment
To assess the quality of the studies, we applied a quality
rating scale, and determined (using a priori definitions of
high, moderate and low quality) that the evidence base
was of moderate quality. To rate the strength and stability
of this evidence, we used the moderate quality branch of
the system, which is not included in this paper, but is
structurally very similar to the high quality arm. The key
difference is an across-the-board decrease in both stability
and strength ratings (e.g., "Strong" in the high quality
branch corresponds to "Moderate" in the moderate qual-
ity branch).
Sufficient data for quantitative estimate
A priori, we decided that an evidence base could be consid-
ered sufficient to permit a quantitative estimate if there
were at least three studies and also if at least 75% of the
included studies had reported effect sizes or had provided
sufficient information for the calculation of effect sizes. In
this case, there were five studies, and both sensitivity andBMC Medical Research Methodology 2006, 6:52 http://www.biomedcentral.com/1471-2288/6/52
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specificity were calculable for all five studies. Therefore,
we proceeded with the quantitative analysis.
Heterogeneity testing
A priori, we defined quantitatively consistent results as an
I2 of less than 50% (see above). We computed the diag-
nostic odds ratio for each of the five studies, and the het-
erogeneity test revealed no heterogeneity (I2  = 0%).
Therefore, based on the definition of quantitative consist-
ency, we deemed these findings to be quantitatively con-
sistent. There was a threshold effect in the data, however,
as evidenced by a plot of the data in ROC space and a
strong negative correlation between sensitivity and specif-
icity. We used the method of Littenberg and Moses [25] to
construct a symmetric summary ROC curve, and com-
puted a summary diagnostic odds ratio of 12.7 (95% con-
fidence interval 5.5 to 29.7). At the mean threshold in the
included studies, this estimate corresponded to a sensitiv-
ity of 64% and a specificity of 88%.
Informativeness
When evaluating this diagnostic, we attempted to reach
only quantitative conclusions, not qualitative conclu-
sions. Therefore, we did not consider informativeness,
and we automatically proceeded to quantitative robust-
ness testing for the summary diagnostic odds ratio (DOR).
Quantitative robustness testing
A priori, we defined a quantitatively robust evidence base
as one that met both of the following two conditions: 1)
the confidence interval around the summary DOR did not
contain a DOR 50% higher or lower than the summary
point estimate, and 2) a cumulative meta-analysis in
which studies were entered by precision (highest preci-
sion study first) found that all of the last three analyses
produced summary effects that were within 5% of the
overall summary diagnostic odds ratio. In this case, the
evidence base met neither of these conditions; therefore,
we deemed the estimate to be not robust.
Stability rating
Using the system, we assigned a stability rating of Low to
the estimated diagnostic odds ratio of 12.7 (95% CI 5.5 to
29.7). This rating was based on the fact that the studies
were of moderate quality, and the estimate was not quan-
titatively robust.
Wording of conclusions
The conclusion was phrased in the following manner:
For the detection of bone marrow infiltration, at mean
threshold PET has a sensitivity of 64% (95% CI: 43% to
80%), and a specificity of 88% (95% CI: 76% to 95%).
Stability of estimate: Low.
Discussion
The rating system described in this paper has several
unique attributes. First, it distinguishes quantitative sta-
bility ratings from qualitative strength ratings. Second, it
makes extensive use of a priori judgments to avoid bias.
Third, it makes explicit the consequences of the results of
meta-analysis and sensitivity analyses for both stability
ratings and strength ratings. We have linked these
attributes, and many others, into a logically consistent sys-
tem intended to improve the process of systematic review.
Our system recognizes the fundamental role of judgment
in summarizing evidence. The system is best viewed as a
logical way to organize one's own judgments, not a prede-
fined list of required judgments. Because different analysts
can have different judgments, however, there is a critical
need for transparency. This allows the user to trace the
path of judgments that lead to a stability or strength rat-
ing. In fact, to use our system without making judgments
explicit would constitute a misuse of the system.
Explicitness in judgments has been advocated by the
GRADE group [2], but explicitness is not sufficient. Wher-
ever possible, judgments should be made a priori and
should be empirically-based. A priori judgments, a natural
extension of a priori inclusion criteria, may help reduce
bias by avoiding the influence of observed data on opera-
tional definitions. Also, basing judgments on empirical
analyses, rather than opinion alone, may reduce bias. For
example, judgments about quantity can be made empiri-
cally-based via formal sensitivity analysis.
While our system allows different analysts to make differ-
ent judgments, it does place certain boundaries on judg-
ments. If there are only one or two studies, for example,
the evidence base must be judged insufficient to permit a
quantitative estimate of the effect size. Further, if these
one or two studies are of low quality, then no conclusion
is possible. If there is only one study, then it must have
been a high quality study observing a large effect in order
to permit any conclusion. These limitations for small evi-
dence bases are grounded in the principle of independent
replication of scientific findings.
The GRADE system also places certain boundaries on the
kinds of judgments permitted. In GRADE, one must give
high priority to randomization: RCTs are initially judged
as two levels stronger than observational studies, and
three levels stronger than other study designs. Also,
GRADE defines a "strong" association as a relative risk
between 2 and 5 (or between 0.2 and 0.5) and a "very
strong" association as a relative risk greater than 5 (or less
than 0.2) (see Note 8). Other judgments are left up to the
analyst, although GRADE recommends that all judgments
be made explicit.BMC Medical Research Methodology 2006, 6:52 http://www.biomedcentral.com/1471-2288/6/52
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We next note some potential limitations of the system
described in this paper. First, the system is complex.
Understanding how it works, and more importantly why
it works that way, requires careful study. Second, the sys-
tem is resource-intensive, mostly because of the numerous
a priori judgments. The analyst is responsible for making
reasonable judgments before analyzing the data. For
example, the a priori definition of a "clinically significant
effect" is a critical judgment that can greatly impact the
conclusions of the review. One strategy we have employed
is to have additional clinicians and methodologists exam-
ine the analyst's a priori judgments for their reasonable-
ness, and then to resolve disagreements in conference.
These consensus judgments are then employed through-
out the step-by-step system to produce evidence ratings.
Whatever judgments are agreed upon, however, should be
made fully explicit in the review. Such transparency, as
emphasized throughout this paper, can enhance the flexi-
bility and usefulness of the review.
In summary, explicit judgments and formal combination
rules, as advocated by the GRADE group, represent two
important steps on the path to a fully reliable system for
rating medical evidence. Throughout this paper, we have
argued that many additional steps must be taken. Fore-
most among these are distinguishing between quantita-
tive and qualitative conclusions, making a priori
judgments to avoid bias, and directly linking analytic
results to evidence ratings.
Considered as a whole, our system constitutes a flexible
tool for incorporating the full complexity of the evidence.
Despite this complexity, the system outputs straightfor-
ward conclusions and ratings for medical decision makers
to employ as they encounter difficult evidence-based deci-
sions.
Summary
￿ Systematic reviewers inevitably make judgments about
the quality, quantity, consistency, robustness, and magni-
tude of effects observed in the studies identified
￿ This paper introduces a formal system for combining
these judgments in a logical, consistent framework
￿ Unique aspects of the system include the distinction
between quantitative and qualitative conclusions, exten-
sive a priori criteria for judgments, and the direct impact of
meta-analysis and sensitivity analysis on evidence ratings
￿ Stability ratings refer to the likelihood that future evi-
dence will indicate a different size of effect
￿ Strength ratings refer to the likelihood that future evi-
dence will overturn conclusions about whether a device,
drug or procedure is effective (or harmful)
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Notes
1 – Throughout this paper, the word "technology" is used
generically to refer to drugs, devices, or procedures.
2 – The specific outcome could be a surrogate outcome or
a patient-oriented outcome.
3 – The presence of heterogeneity is a violation of the
assumption of fixed-effects models: that the available data
are sampled from a single distribution that describes a sin-
gle summary estimate of treatment effect.
4 – The use of 0 assumes that the effect size metric is cen-
tered around 0 (e.g., the standardized difference between
means). Other effect size metrics (e.g., relative risk, odds
ratio) are centered around 1, and for these one would
determine whether the random-effects confidence interval
were fully above 1 or below 1.
5 – We refer to an entire family of procedures designed to
assess the sensitivity of one's conclusions to certain
aspects of the data or certain analytic assumptions. Many
of these were listed in a paper by Olkin,[26] and some
examples include publication bias testing, [27-29] cumu-
lative meta-analysis, [21,30] and the removal of specific
subsets of the data.
6 – Although not illustrated in the figure, there are possi-
ble effect sizes corresponding to A through D that would
fall on the left side of the graph (below zero). Some of
these possibilities would lead to a conclusion that theBMC Medical Research Methodology 2006, 6:52 http://www.biomedcentral.com/1471-2288/6/52
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treatment was either harmful or inferior to a comparison
treatment.
7 – TRICARE is the government agency under the Depart-
ment of Defense responsible for administering the health
benefits for the U.S. armed forces and their dependants.
8 – Note that the GRADE system's treatment of effect mag-
nitude does not specifically mention the confidence inter-
val around the effect. Instead the system addresses
imprecise or sparse data in a separate manner. Our system
considers an effect size and its confidence interval simul-
taneously.
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